Schumacher, Sofie http://orcid.org/0000-0002-8805-1421
Salmanton-García, Jon http://orcid.org/0000-0002-6766-8297
Cornely, Oliver A. http://orcid.org/0000-0001-9599-3137
Mellinghoff, Sibylle C. http://orcid.org/0000-0003-3928-2503
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Received: 1 October 2020
Accepted: 6 November 2020
First Online: 7 December 2020
Compliance with ethical standards
:
: SS and JSG declare that they have no conflicts of interest. OAC is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—CECAD, EXC 2030–390661388 and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen, Medicines Company, Melinta, Merck/MSD, Octapharma, Pfizer, Scynexis, is a consultant to Actelion, Allecra, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini, Merck/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi, and received lecture honoraria from Al-Jazeera Pharmaceuticals, Astellas, Basilea, Gilead, Grupo Biotoscana, Merck/MSD and Pfizer. SCM was a consultant to Octapharma. She has been receiving research grants from the University Hospital of Cologne (KoelnFortune), from the German center for infection research (DZIF; Clinical Leave Stipend), and from the German Mycological Society (Dr. Manfred Plempel Stipend).